Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline
Status:
Terminated
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and
octreotide therapy is superior to the standard of care alone in the treatment of Type I
hepatorenal syndrome in the first 14 days of hospitalization.